---
canonical_name: Caralluma fimbriata
alternate_names: Caralluma adscendens var. fimbriata, Caralluma fimbriata Wall. ex Wight, Caralluma fimbriata Extract, CFE, Slimaluma
canonical_topic: Caralluma fimbriata for Health & Longevity
short_topic_lc: caralluma_fimbriata
creation_date: 2026-0825-0943
creator_ai_fullname: Opus 5
ep_keywords: Appetite Suppressants, Weight Loss Supplements, Pregnane Glycosides
---

# Caralluma fimbriata for Health & Longevity
<section id="top" markdown="1"></section>  
Evidence Review created on 08/25/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5

**Also known as:** Caralluma adscendens var. fimbriata, Caralluma fimbriata Wall. ex Wight, Caralluma fimbriata Extract, CFE, Slimaluma

  
## Motivation

<!-- Author's statement: this Motivation section was written last, after every other section of this review had been completed, so that it reflects the full scope of the evidence examined rather than a preview written in advance. -->

*Caralluma fimbriata* is a small, edible succulent that grows wild across the drier parts of India, where villagers have long eaten it boiled, pickled, or raw. Tribal hunters are said to have chewed the stems to hold off hunger and thirst on long treks. Since the early 2000s a concentrated extract of the plant has been sold worldwide in capsule form as a natural appetite suppressant and weight-management aid.

The plant's appeal rests on a simple idea: that something people have eaten as food for generations might blunt hunger without the cost, prescription requirement, or side-effect burden of modern weight-loss medicines. United States regulators have accepted one branded extract as safe for use in food, while European authorities declined to approve the marketing claims made for it. That split has left the plant widely available but unevenly judged.

This review examines what controlled human trials, pooled analyses, animal work, and safety testing actually show about *Caralluma fimbriata* — where the signals are real, where they are absent, where they conflict, and how much of the published record comes from parties who sell the extract.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**

  
## Recommended Reading

A short, curated set of high-level sources that give useful orientation on *Caralluma fimbriata* before the detailed evidence sections.

<!-- Author's search statement: on 17 August 2026 a real-time web search was run for "Caralluma fimbriata" combined with each priority platform (foundmyfitness.com, peterattiamd.com, hubermanlab.com, chriskresser.com, lifeextension.com, lifespan.io) using both general web search and each site's own search function. Life Extension's on-site search returned no caralluma content; site-scoped web searches for the other five platforms returned no caralluma content either. A broader search of PubMed and the open web was then run for narrative reviews, primary clinical trials, and expert commentary discussing the plant by name in substantial depth. -->

- [Delving the Role of Caralluma fimbriata: An Edible Wild Plant to Mitigate the Biomarkers of Metabolic Syndrome](https://pubmed.ncbi.nlm.nih.gov/35770046/) - Anwar et al., 2022

  The broadest narrative overview available: nutritional composition, bioactive constituents, safety data, and therapeutic claims for metabolic syndrome, assembled by an independent academic group with no extract manufacturer involved.

- [Pharmacological review of Caralluma R.Br. with special reference to appetite suppression and anti-obesity](https://pubmed.ncbi.nlm.nih.gov/22191633/) - Dutt et al., 2012

  Places the plant in its botanical genus, catalogues the pregnane glycoside chemistry thought to drive appetite suppression, and explains how the branded Slimaluma extract reached the market.

- [Effect of Caralluma fimbriata extract on appetite, food intake and anthropometry in adult Indian men and women](https://pubmed.ncbi.nlm.nih.gov/17097761/) - Kuriyan et al., 2007

  The first randomised placebo-controlled human trial of the extract and the origin of nearly every claim made for it since. Useful for judging how modest the original findings actually were.

- [The effect of an orally-dosed Caralluma Fimbriata extract on appetite control and body composition in overweight adults](https://pubmed.ncbi.nlm.nih.gov/33762661/) - Rao et al., 2021

  The longest and largest trial to date, run by a contract research organisation on an industry-supplied extract. Shows what a well-resourced, commercially sponsored study of the ingredient produces.

- [Single-Case Study of Appetite Control in Prader-Willi Syndrome, Over 12-Years by the Indian Extract Caralluma fimbriata](https://pubmed.ncbi.nlm.nih.gov/31212875/) - Griggs, 2019

  A twelve-year continuous-use record with routine blood, liver, thyroid, and metabolic testing — the only published account of very long-term human exposure to the extract.

No content on *Caralluma fimbriata* was found on any of the six priority expert platforms listed in this review's source criteria; searches of each platform's own search function and site-scoped web searches both returned nothing, so no priority-expert item could be included.

  
## Grokipedia

<!-- Author's search statement: grokipedia.com was searched directly with the browser tool on 17 August 2026 for "Caralluma fimbriata". No article exists under that name; the site's dedicated article is filed under the currently accepted botanical name, Caralluma adscendens, of which C. fimbriata is treated as a variety and synonym, and that article covers the fimbriata variety, its extract, and its regulatory status directly. -->

- [Caralluma adscendens](https://grokipedia.com/page/caralluma_adscendens)

  Grokipedia files the plant under its accepted botanical name. The article covers the fimbriata variety's chemistry, traditional use, safety findings, and the divergent United States and European regulatory decisions on its extract.

  
## Examine

<!-- Author's search statement: examine.com was searched directly on 17 August 2026 for "Caralluma". The site's own search endpoint was behind a bot-detection interstitial, so the supplement page was retrieved directly and confirmed to be the site's dedicated, primary entry for this ingredient. -->

- [Caralluma Fimbriata](https://examine.com/supplements/caralluma-fimbriata/)

  Examine's dedicated ingredient page. It grades the single overweight-related outcome at its lowest evidence tier and notes the only human dosing lead is 1,000 mg daily of concentrated extract.

  
## ConsumerLab

<!-- Author's search statement: consumerlab.com was searched directly on 17 August 2026 for "caralluma". The search returned a general appetite-suppressant answer article, a general weight-loss supplement product review, and four regulatory warning items, but no product review, clinical update, or answer article dedicated to Caralluma fimbriata. ConsumerLab has never published independent laboratory testing of caralluma products. -->

No ConsumerLab review, answer article, or clinical update dedicated to *Caralluma fimbriata* exists. The ingredient appears only inside broader appetite-suppressant and weight-loss coverage and in enforcement warnings about weight-loss marketers, so there is no primary ConsumerLab page for this intervention to link to.

  
## Systematic Reviews

Pooled analyses that have formally assessed *Caralluma fimbriata* against placebo, either on its own or within a wider set of botanical weight-management agents.

<!-- Author's search statement: PubMed was searched on 17 August 2026 with the query "Caralluma fimbriata AND (systematic review[pt] OR meta-analysis[pt] OR systematic review OR meta-analysis)", returning five records. One was a primary crossover trial and is excluded here; the remaining four are listed below and were prioritised by direct relevance to the intervention, then by study count and recency. -->

- [The use of Caralluma fimbriata as an appetite suppressant and weight loss supplement: a systematic review and meta-analysis of clinical trials](https://pubmed.ncbi.nlm.nih.gov/34758791/) - Jayawardena et al., 2021

  The only pooled analysis devoted solely to this plant; seven trials, significant waist and waist-to-hip reductions, no weight, appetite, or biochemical benefit.

- [Effect of the herbal medicines in obesity and metabolic syndrome: A systematic review and meta-analysis of clinical trials](https://pubmed.ncbi.nlm.nih.gov/31793087/) - Payab et al., 2020

  Screened 279 trials of botanical agents and ranked *Caralluma fimbriata* among the minority with both weight-management and appetite-reducing signals worth further study.

- [Plant extracts with appetite suppressing properties for body weight control: a systematic review of double blind randomized controlled clinical trials](https://pubmed.ncbi.nlm.nih.gov/23876572/) - Astell et al., 2013

  Of fourteen double-blind trials of appetite-suppressing plant extracts, this plant was one of only two exceptions to an otherwise inconclusive body of evidence.

- [Modulation of the hypothalamic-pituitary-adrenal (HPA) axis by plants and phytonutrients: a systematic review of human trials](https://pubmed.ncbi.nlm.nih.gov/33650944/) - Lopresti et al., 2022

  Places the plant's stress-hormone claim among 25 other botanicals and concludes the human cortisol evidence for most of them, including this one, remains unclear.

The claimed-effect side of the trade-off is well represented above. The principal risk side — digestive tolerability and long-term safety of the extract — has no systematic review or meta-analysis of its own; the safety record rests on individual trial adverse-event tables and animal toxicology, and that gap is unrepresented in the pooled literature.

  
## Mechanism of Action

*Caralluma fimbriata* is a multi-component botanical rather than a single molecule. Its extract is standardised to pregnane glycosides (steroid-like plant sugars that are also the presumed active fraction of the related appetite-suppressing succulent *Hoodia gordonii*) alongside flavone glycosides and beta-sitosterol. A [phytochemical analysis of a commercially available extract](https://pubmed.ncbi.nlm.nih.gov/28713048/) measured roughly 12% pregnane glycosides and 1.3% polyphenols.

Two mechanisms are proposed. Centrally, the extract is thought to act on the hypothalamus (the brain region that sets hunger and fullness). A [mouse study](https://pubmed.ncbi.nlm.nih.gov/30353709/) implicates the serotonin 2C receptor (a brain switch that signals satiety): blocking that receptor abolished the extract's food-intake reduction. Peripherally, the extract is proposed to inhibit citrate lyase (an enzyme in the pathway that builds new body fat) and so lower malonyl-CoA (the intermediate that pathway runs on), which would shift metabolism toward burning stored fat.

The central account is directly contested. One [rat study](https://pubmed.ncbi.nlm.nih.gov/28713048/) found reduced weight gain alongside *increased* hypothalamic neuropeptide Y and orexin (two brain messengers that normally drive eating), the opposite of what simple hunger-signal suppression predicts, and pointed instead to peripheral digestive-enzyme effects.

No human pharmacokinetic study exists: half-life, tissue distribution, metabolic route, and the enzymes responsible for clearance are all uncharacterised in people.

  
## Historical Context & Evolution

*Caralluma fimbriata* entered use as food, not medicine. It grows wild along roadsides and field edges across peninsular India and was eaten as a boiled, salted, or pickled vegetable and preserved in chutneys. In Sanskrit and regional Indian sources it appears among famine foods — plants relied on when harvests failed. Ethnobotanical accounts describe tribal hunters chewing the stems to suppress hunger and thirst during long pursuits, and the related genus was used traditionally for rheumatism, diabetes, and inflammation.

That hunger-suppressing reputation is what carried it into health optimisation. In the late 1990s and early 2000s, commercial interest in *Hoodia gordonii* — a southern African succulent whose pregnane glycosides were being developed as an appetite suppressant — prompted a search for related plants with the same chemistry and a longer human food history. *Caralluma fimbriata* fit: same compound class, centuries of dietary use, no endangered-species restrictions.

A standardised hydroethanolic extract was commercialised and tested in a [first randomised trial in 2007](https://pubmed.ncbi.nlm.nih.gov/17097761/). The evidence base has since diverged rather than converged: an [independent Indian trial](https://pubmed.ncbi.nlm.nih.gov/25657901/) found nothing beyond placebo, a [manufacturer-linked Australian trial](https://pubmed.ncbi.nlm.nih.gov/33762661/) found body-composition effects, and a [2021 pooled analysis](https://pubmed.ncbi.nlm.nih.gov/34758791/) concluded the extract could not be recommended. Regulators split the same way, with United States and European authorities reaching opposite conclusions.

  
## Expected Benefits

<!-- Author's search statement: before writing this section, a dedicated benefit-profile search was run on 17 August 2026 across PubMed (37 records for "Caralluma fimbriata", reviewed in full), ClinicalTrials.gov, Examine.com, Grokipedia, and general web search, to confirm that every claimed or demonstrated benefit domain — appetite, body composition, waist circumference, lipids, glucose, blood pressure, stress and anxiety, hyperphagia, vascular function, and organ protection — was captured and graded. -->

### High 🟩 🟩 🟩

#### Modest Reduction in Waist Circumference and Waist-to-Hip Ratio

This is the only outcome that survives pooling. A [meta-analysis of seven clinical trials](https://pubmed.ncbi.nlm.nih.gov/34758791/) found significant reductions in waist circumference and waist-to-hip ratio versus placebo, while body weight, body mass index (a weight-for-height ratio), and hip circumference showed no significant change. For a longevity-focused reader the distinction matters: central fat is more closely tied to metabolic risk than total mass. The effect is small, the confidence interval (the range likely to contain the true effect) nearly touches zero, and most contributing trials were small and industry-linked.

**Magnitude:** Pooled reduction of 1.59 cm in waist circumference (95% confidence interval −3.07 to −0.10) and 0.06 in waist-to-hip ratio (95% confidence interval −0.12 to −0.01) across seven trials.

### Medium 🟩 🟩

#### Attenuation of Weight Gain Without Deliberate Calorie Restriction ⚠️ Conflicted

In a [16-week randomised controlled trial](https://pubmed.ncbi.nlm.nih.gov/33762661/) (a study in which participants are randomly assigned to treatment or placebo), 83 overweight adults on an uncontrolled diet gained weight on placebo but not on the extract, with the placebo group also gaining fat mass and body mass index. The finding is weight-gain prevention, not weight loss. It is directly contradicted by an [independent trial in 89 overweight adults](https://pubmed.ncbi.nlm.nih.gov/25657901/) that found no anthropometric benefit over placebo, and by the pooled null result for body weight.

**Magnitude:** Over 16 weeks, a 0.37 kg loss on extract versus a 1.33 kg gain on placebo; the pooled analysis found no significant body-weight or body mass index difference across trials.

#### Reduced Hunger and Self-Reported Energy Intake ⚠️ Conflicted

The founding claim. The [first randomised trial](https://pubmed.ncbi.nlm.nih.gov/17097761/) in 50 overweight Indian adults found a significant decline in hunger ratings versus placebo over 60 days, and the 16-week trial found a large drop in self-reported calorie intake; a [crossover pilot trial](https://pubmed.ncbi.nlm.nih.gov/26713299/) in 15 children with Prader-Willi syndrome (a genetic disorder causing uncontrollable hunger) eased parent-rated hyperphagia (extreme hunger). Against this, the [pooled analysis](https://pubmed.ncbi.nlm.nih.gov/34758791/) found no significant change in appetite parameters, and the independent Indian trial found none at all. Self-reported intake is a weak endpoint prone to reporting bias.

**Magnitude:** Self-reported intake fell by 245 kcal/day on extract versus 15.8 kcal/day on placebo at 16 weeks; hyperphagia scores eased in roughly one-third of 15 Prader-Willi participants; pooled appetite scores showed no significant change.

### Low 🟩

#### Reduced Subjective Anxiety and Perceived Stress

An [8-week randomised trial](https://pubmed.ncbi.nlm.nih.gov/30609411/) in 97 adults with self-reported mild-to-moderate anxiety found greater improvement on standard anxiety and perceived-stress questionnaires than placebo at both 4 and 8 weeks. Salivary cortisol shifted significantly in men only. A single trial with subjective primary endpoints supports no stronger grade.

**Magnitude:** Greater reduction than placebo on the anxiety and perceived-stress questionnaires at both 4 and 8 weeks; the trial reports no between-group effect size for these outcomes.

### Speculative 🟨

#### Vascular and Endothelial Protection

In [obese mice on a high-fat diet](https://pubmed.ncbi.nlm.nih.gov/39770917/), the extract improved blood-vessel function. Basis is animal-only; no human vascular endpoint has been measured in any trial of this extract.

#### Protection of Liver and Kidney From Diet-Induced Oxidative Stress

Multiple rat studies, including one on [kidney protection](https://pubmed.ncbi.nlm.nih.gov/28911565/), report reduced organ oxidative damage on high-fat diets. Basis is rodent-only; human trials measured liver and kidney markers as safety checks, not benefits.

#### Improved Glucose Handling and Insulin Sensitivity

In [high-fat-fed rats](https://pubmed.ncbi.nlm.nih.gov/24474087/), the extract eased insulin resistance and oxidative stress. Basis is rodent and laboratory work only; human trials found no change in glucose or insulin measures.

#### Improved Blood Lipid Profile and Protection Against Atherosclerosis

In [cafeteria-diet-fed rats](https://pubmed.ncbi.nlm.nih.gov/21234320/), the extract blocked diet-driven serum lipid shifts and protected against arterial plaque formation. Basis is rodent-only; human trials found no lipid change.

  
## Benefit-Modifying Factors

- **Baseline central adiposity:** The waist-circumference signal was measured almost entirely in adults with a body mass index above 25 or an elevated waist. Lean individuals with normal waist measurements have no trial data and no plausible room for the observed effect.

- **Baseline hunger drive:** The clearest responses appear where hunger is abnormally high — the Prader-Willi cohort and self-reported over-eaters. Adults already eating to appetite in a controlled way have less signal available to move.

- **Sex:** The stress trial found statistically significant salivary cortisol changes in men but not women, while the body-composition trial was 90% female. Sex-specific efficacy therefore remains genuinely untested for most endpoints.

- **Concurrent diet and activity control:** The [trial showing the largest waist reduction](https://pubmed.ncbi.nlm.nih.gov/23642949/) also controlled diet and exercise, and its placebo group improved substantially too. Benefit attributable to the extract alone shrinks when background behaviour is already optimised.

- **Age:** All trials enrolled adults aged roughly 18–60, with a mean near 40. No efficacy data exist above 65, where appetite suppression is more likely to be a liability than a benefit given age-related loss of muscle mass.

- **Genetic variation:** No pharmacogenetic study exists. Variants in *HTR2C* (the gene encoding the serotonin 2C receptor implicated in the animal mechanism work) are a plausible but entirely untested source of response variability.

- **Pre-existing metabolic disease:** Trials excluded people with diabetes and uncontrolled metabolic disease, so benefit in that group — where appetite suppression could matter most — is unmeasured.

  
## Potential Risks & Side Effects

<!-- Author's search statement: before writing this section, a dedicated safety-profile search was run on 17 August 2026 across PubMed (including the dedicated toxicology assessment and every human trial's adverse-event reporting), the Examine.com ingredient page, WebMD's drug-and-supplement monograph, ConsumerLab's regulatory warning archive, Grokipedia's regulatory section, and general web search, to confirm no reported adverse-effect class was omitted. -->

### High 🟥 🟥 🟥

#### Gastrointestinal Disturbance

The dominant and best-documented adverse-effect class. The [pooled review of seven trials](https://pubmed.ncbi.nlm.nih.gov/34758791/) identifies constipation, diarrhoea, and nausea as the most common reported effects, and individual trials describe abdominal discomfort and flatulence, typically in the first one to two weeks. Events across trials are characterised as mild and transient, and no trial reported discontinuation driven by them. Mechanism is unestablished; direct action on digestive enzymes and gut motility is the leading proposal.

**Magnitude:** Constipation, diarrhoea, and nausea are consistently the most frequently reported events at 1 g daily and typically ease after the first fortnight; few trials reported incidence rates, so the literature provides no pooled frequency figure.

### Medium 🟥 🟥

#### Cutaneous Hypersensitivity Reactions

Skin rashes appear in the [pooled adverse-event list](https://pubmed.ncbi.nlm.nih.gov/34758791/) alongside the digestive effects. The plant belongs to the *Apocynaceae* family, several members of which contain irritant latex compounds, giving a plausible allergic or irritant basis. Reported cases were mild and resolved on discontinuation. No confirmed case of severe hypersensitivity has been published, but trial populations are far too small to detect rare severe reactions.

**Magnitude:** Rash is reported across trials at 1 g daily and resolves on stopping; individual trials did not report rash incidence separately, so the literature provides no rate figure.

#### Product Adulteration, Species Substitution, and Mislabelling

The larger practical risk is the product rather than the plant. Weight-loss supplements are a high-adulteration category, and analytical work on the genus has required dedicated chromatographic methods to [distinguish and quantify pregnane content across *Caralluma* species](https://pubmed.ncbi.nlm.nih.gov/22165002/), which are visually similar and readily substituted. United States consumer-protection enforcement against marketers of caralluma weight-loss products has involved fabricated celebrity endorsements and unsubstantiated claims.

**Magnitude:** Risk concentrates in products sold through direct-response marketing rather than through third-party-tested brands; no published survey has measured how often commercial caralluma products fail content or identity testing, so the literature gives no failure-rate figure.

### Low 🟥

#### Unverified Safety in Pregnancy and Lactation ⚠️ Conflicted

The evidence points both ways. A [formal toxicological assessment](https://pubmed.ncbi.nlm.nih.gov/23771637/) found no fetal abnormalities in rats and no genetic damage in two standard assays, yet a [drug-and-supplement monograph](https://www.webmd.com/vitamins/ai/ingredientmono-1160/caralluma) still advises against use in pregnancy and breastfeeding because human safety is unknown. Every trial excluded pregnant and breastfeeding women.

**Magnitude:** Not quantified in available studies. No controlled human pregnancy or lactation exposure has ever been studied, so neither an event rate nor an effect size exists.

#### Absence of Human Safety Data Beyond Sixteen Weeks

The longest randomised trial ran [16 weeks](https://pubmed.ncbi.nlm.nih.gov/33762661/). For an intervention marketed for continuous use, that leaves indefinite supplementation unstudied. The only long-term human record is a [single published case followed over twelve years](https://pubmed.ncbi.nlm.nih.gov/31212875/) with normal blood count, liver, thyroid, and metabolic testing throughout — reassuring but uncontrolled and unrepeated.

**Magnitude:** Not quantified in available studies. No controlled trial has run beyond 16 weeks, so no long-term adverse-event rate has been measured.

### Speculative 🟨

#### Serotonergic Interaction With Psychiatric Medication

Animal work implicates the serotonin 2C receptor in the extract's appetite effect. Basis is mechanistic and rodent-only; no human interaction study with any serotonergic medication has been performed.

#### Hypoglycaemia When Combined With Glucose-Lowering Therapy

Rodent studies report antihyperglycaemic activity, so hypoglycaemia (blood sugar dropping below normal) is plausible; human trials excluded people with diabetes. Basis is animal data plus mechanism only; no human case has been published.

  
## Risk-Modifying Factors

- **Pre-existing digestive conditions:** Irritable bowel syndrome, chronic constipation, or gastroparesis (delayed stomach emptying) plausibly amplify the dominant adverse-effect class, since the extract's most consistent effects are digestive.

- **Baseline liver and kidney function:** Impairment concentrates any unmetabolised plant constituents, and human clearance routes are uncharacterised. Trials excluded liver and kidney disease, so this group has no safety data.

- **Sex:** No sex difference in adverse events has been reported, but the largest body-composition trial was roughly 90% female and the stress trial found sex-specific hormone effects, so male tolerability data are thin.

- **Age:** Above 65, appetite suppression itself becomes the hazard — reduced protein intake accelerates muscle loss. No trial enrolled participants beyond about 60, so this risk is inferred, not measured.

- **Diabetes and glucose-lowering medication:** Rodent antihyperglycaemic activity plus excluded human data make additive glucose lowering an unquantified but plausible concern in anyone on insulin or sulfonylureas.

- **Genetic variation:** No pharmacogenetic data exist. Variants affecting serotonin 2C receptor function or drug-metabolising enzymes are plausible modifiers of both response and tolerability but have never been studied for this extract.

- **Pregnancy and breastfeeding:** Categorically excluded from every trial, with conflicting animal and reference-source signals, making this the clearest risk-modifying state.

  
## Key Interactions & Contraindications

No formal human drug-interaction study of *Caralluma fimbriata* has ever been performed. Every interaction below is inferred from mechanism, trial exclusion criteria, or class effects, and none has been confirmed clinically.

- **Anticoagulants and antiplatelet drugs (blood-thinning medicines such as warfarin, heparin, dalteparin, enoxaparin):** Caution. The registered stress trial excluded all users of these agents. Consequence if an interaction exists would be altered clotting; separation or monitoring of clotting times is the stated mitigation.

- **Glucose-lowering drugs (insulin, sulfonylureas such as glipizide, metformin):** Caution, additive effect. Rodent data show antihyperglycaemic activity; combined with reduced food intake the consequence is hypoglycaemia. Mitigation is increased glucose self-monitoring during the first month.

- **Serotonergic psychiatric medication (selective serotonin reuptake inhibitors such as sertraline, appetite drugs acting on serotonin receptors):** Caution. Animal work places the extract's effect at the serotonin 2C receptor, so additive appetite suppression or serotonergic effects are plausible.

- **Prescription weight-loss agents (glucagon-like peptide-1 receptor agonists such as semaglutide, phentermine):** Caution, additive. Consequence is excessive appetite suppression with inadequate protein and micronutrient intake. Mitigation is not combining, or tracking protein intake weekly.

- **Over-the-counter agents (bulk-forming laxatives, psyllium, loperamide, bismuth subsalicylate):** Monitor. The extract's own digestive effects run in both directions, so these agents may compound constipation or diarrhoea rather than correct it.

- **Supplements with additive appetite or glucose effects (*Gymnema sylvestre*, *Garcinia cambogia*, glucomannan, berberine, chromium):** Caution. Appetite-suppressant and glucose-lowering stacking is the most common real-world exposure and is entirely unstudied for this combination.

- **Other interventions (prolonged fasting, aggressive calorie restriction, high-volume endurance training):** Caution. Layering pharmacological appetite suppression onto an already restricted intake risks under-fuelling and lean-mass loss in this audience specifically.

**Populations who should avoid Caralluma fimbriata:**

- Pregnant or breastfeeding women — excluded from every trial; negative animal toxicology but unknown human safety
- Children and adolescents outside a supervised Prader-Willi protocol — no general paediatric safety data
- Adults with a current or past eating disorder — appetite suppression is directly contraindicated
- Adults with clinically significant liver or kidney impairment (estimated glomerular filtration rate, a kidney-filtering measure, below 45 mL/min/1.73 m², or Child-Pugh Class B or C liver disease) — excluded from all trials
- Adults above 65 with sarcopenia (age-related loss of muscle mass and strength) or unintentional weight loss — appetite suppression compounds muscle loss
- Anyone with known *Apocynaceae* family plant allergy — cross-reactivity risk

  
## Risk Mitigation Strategies

- **Half-dose introduction for two weeks:** A 500 mg daily start rather than the studied 1 g, escalating afterwards. This is aimed squarely at the dominant risk — first-fortnight constipation, diarrhoea, and nausea, which trials describe as transient.

- **Take with food, split morning and evening:** Every trial dosed 500 mg twice daily with meals. Taking capsules on an empty stomach is the most common self-reported trigger for nausea and abdominal discomfort.

- **Third-party-tested product only:** A certificate of analysis confirming species identity and pregnane glycoside content is the operative requirement. This addresses the species-substitution and mislabelling risk, the single largest practical hazard in this category.

- **Protein floor of 1.6 g/kg body weight daily:** Deliberate appetite suppression reduces total intake indiscriminately. Setting and tracking a protein floor prevents the lean-mass loss that makes weight reduction counterproductive for longevity.

- **Baseline and 12-week liver and kidney panels:** Human clearance routes are uncharacterised and trials excluded organ impairment. Testing before and after one cycle detects any individual biochemical drift early.

- **Sixteen-week ceiling per cycle, then reassess:** No controlled human data exist beyond 16 weeks. Stopping at the edge of the evidence base and re-evaluating avoids indefinite exposure at an unstudied duration.

- **Discontinue immediately on rash:** Cutaneous reactions reported in trials resolved on stopping. Continuing through a rash risks escalation, and no severe-reaction data exist to define a safe threshold.

- **Glucose self-monitoring if on diabetes medication:** Daily fasting glucose readings across the first two weeks. This targets the plausible additive hypoglycaemia risk from combined appetite suppression and rodent-demonstrated glucose lowering.

  
## Therapeutic Protocol

- **Standard protocol:** 500 mg of standardised hydroethanolic extract twice daily with food, totalling 1 g daily. This is the dose used in every published randomised trial, across 8, 12, and 16-week durations.

- **Standardised extract approach:** The branded hydroethanolic extract commercialised by Gencor Pacific under the name Slimaluma is the form used in essentially all clinical trials and the form holding United States food-ingredient clearance.

- **Whole-plant traditional approach:** Indian culinary use consumes boiled, salted, or pickled stems as a vegetable in unquantified amounts. No trial has tested whole-plant intake, and pregnane glycoside content per serving is unknown.

- **Higher-dose supervised approach:** The Victoria University Melbourne group's [Prader-Willi work](https://pubmed.ncbi.nlm.nih.gov/26713299/) titrated slowly to 1,000 mg daily by observed appetite response, the point at which the clearest hyperphagia effect appeared.

- **Timing:** Trials dosed morning and evening with meals. No trial compared timings, so no time-of-day advantage is established; evening dosing has not been linked to sleep disruption in any trial.

- **Half-life:** No human pharmacokinetic study exists. Half-life, absorption, and clearance of the pregnane glycosides are uncharacterised in people, which is why twice-daily dosing is empirical rather than derived.

- **Split versus single dosing:** All trials used split dosing, 500 mg twice daily. Single 1 g dosing has never been tested and would concentrate the digestive adverse-effect load into one exposure.

- **Genetic polymorphisms:** No pharmacogenetic data exist for this extract. *HTR2C* variants affecting serotonin 2C receptor function are the mechanistically plausible candidate but have never been tested against response.

- **Sex-based differences:** The stress trial found salivary cortisol changes significant in men but not women at identical dosing. No dose adjustment by sex is established, and body-composition trials were overwhelmingly female.

- **Age considerations:** Trials enrolled adults aged 18 to about 60. Above 65 no dosing data exist, and appetite suppression conflicts with the protein intake needed to preserve muscle at that age.

- **Baseline biomarkers:** Elevated waist circumference and elevated baseline leptin identify the populations in which trials measured effects. Normal-waist individuals fall outside every studied population.

- **Pre-existing conditions:** Diabetes, uncontrolled metabolic disease, liver disease, kidney disease, thyroid dysfunction, and malignancy were exclusion criteria across trials, so no protocol guidance exists for these groups.

  
## Discontinuation & Cycling

- **Not established as lifelong:** No controlled human data exist beyond 16 weeks. The only long-term record is a [single uncontrolled twelve-year case](https://pubmed.ncbi.nlm.nih.gov/31212875/), so indefinite use rests on one person's experience rather than trial evidence.

- **No withdrawal effects reported:** No trial reported withdrawal symptoms, rebound hyperphagia, or discontinuation effects. The Prader-Willi crossover design included a two-week washout with no adverse events recorded during it.

- **No tapering required:** Trials stopped dosing abruptly at study end without tapering protocols or reported problems. No evidence supports a structured taper for this extract.

- **Cycling is untested but pragmatic:** No trial has compared continuous with cycled use, so no efficacy-maintenance case exists. Cycling in 12–16 week blocks simply keeps exposure within the studied duration.

- **Effect reversal on stopping:** The [16-week trial's](https://pubmed.ncbi.nlm.nih.gov/33762661/) placebo group gained weight while the extract group did not, implying benefit depends on continued intake. No trial followed participants after discontinuation to confirm this.

- **Reassessment trigger:** Absence of any measurable waist change after 12 weeks at full dose matches the null trials rather than the positive ones, and is a reasonable point to stop.

  
## Sourcing and Quality

- **Standardised extract form:** Clinical evidence applies only to hydroethanolic extracts of the aerial parts. Powdered raw herb, tinctures, and unstandardised capsules have no trial data and unknown pregnane glycoside content.

- **Pregnane glycoside content:** [Independent analysis of a commercial extract](https://pubmed.ncbi.nlm.nih.gov/28713048/) measured approximately 12% pregnane glycosides and 1.3% polyphenols. Labels claiming far higher standardisation without an accompanying certificate of analysis warrant scepticism.

- **Species identity verification:** More than 260 *Caralluma* species exist and are visually similar. Chromatographic identity confirmation on the certificate of analysis is the only reliable guard against substitution with a cheaper congener.

- **Third-party testing:** Verification from an independent testing organisation — NSF International, United States Pharmacopeia, or Informed Choice — confirms label content, and separate testing for heavy metals given that raw material is field-collected in India.

- **Adulterant screening:** Weight-loss supplements are among the most frequently adulterated categories, historically with prescription anorectics (appetite-suppressant drugs). A supplier that screens finished product for undeclared pharmaceuticals materially reduces this exposure.

- **Brands and suppliers:** The branded raw material used in nearly all trials is Slimaluma from Gencor Pacific; finished-product brands licensing it disclose this on the label. Unbranded caralluma extracts have no comparable documentation.

- **Dose per serving:** Trial dosing is 500 mg per capsule taken twice daily. Products delivering 250 mg or blending caralluma into proprietary multi-ingredient formulas make trial-equivalent dosing impossible to verify.

  
## Practical Considerations

- **Time to effect:** Appetite changes, where they occur, appeared by about four weeks in trials; waist and body-composition changes required 8 to 16 weeks. Expecting anything measurable inside a month contradicts every published timeline.

- **Common pitfall — expecting weight loss:** The [pooled evidence](https://pubmed.ncbi.nlm.nih.gov/34758791/) shows no significant body-weight effect. The realistic signal is waist reduction and weight-gain prevention, and treating the extract as a weight-loss agent guarantees disappointment.

- **Common pitfall — proprietary blends:** Caralluma is frequently a minor component of multi-ingredient weight-loss formulas at sub-trial doses, making both dose verification and attribution of any effect impossible.

- **Common pitfall — abandoning behaviour change:** In the [trial with the largest waist reduction](https://pubmed.ncbi.nlm.nih.gov/23642949/), the placebo group also improved substantially under controlled diet and activity. The extract's contribution sits on top of behaviour, not in place of it.

- **Regulatory status:** A dietary supplement in the United States; the extract holds an FDA (Food and Drug Administration) no-objection letter for food use to 700 mg daily. European authorities declined its marketing claims and have not authorised it as a novel food.

- **No professional-body position:** No professional association, medical society, or advocacy organisation has issued a position on this ingredient, so no membership-revenue conflict arises on that front. The conflicts here are commercial, not institutional.

- **Structural payer incentive:** At roughly 1–2% of the monthly cost of prescription appetite medication, caralluma sits where insurers and national health systems have an obvious financial incentive to prefer it — a plausible source of structural bias if it ever entered guideline consideration.

- **Cost and accessibility:** Widely available online and in retail at low cost, typically USD 10–25 monthly. Neither price nor access is a meaningful barrier for this audience.

  
## Interaction with Foundational Habits

- **Sleep:** Direction unclear and formally untested. No trial has reported sleep disruption at evening dosing, and no published trial has measured sleep as an outcome. A [completed randomised trial](https://clinicaltrials.gov/study/NCT05232266) with sleep questionnaires as secondary endpoints has not reported results, leaving this the largest open question about evening use.

- **Nutrition:** Direct and potentially blunting. Reduced total intake reduces protein and micronutrient intake proportionally unless intake is deliberately structured. Every trial dosed with meals. Protein-forward meals and a tracked protein floor are the practical safeguard; the extract has no known nutrient-depletion effect of its own.

- **Exercise:** Indirect. No trial measured strength, power, or hypertrophy (muscle growth) outcomes, and no evidence suggests direct blunting of training adaptation. The plausible interference is energetic: appetite suppression during a hypertrophy or high-volume endurance block risks under-fuelling and compromised recovery rather than a molecular blocking effect.

- **Stress management:** Direct and potentially favourable. A [randomised trial](https://pubmed.ncbi.nlm.nih.gov/30609411/) found improvements in perceived stress and anxiety questionnaires alongside salivary cortisol shifts in men, implicating the hypothalamic-pituitary-adrenal axis (the body's main stress-hormone system). [Pooled review of botanicals](https://pubmed.ncbi.nlm.nih.gov/33650944/) judged the human cortisol evidence for this plant unclear.

  
## Monitoring Protocol & Defining Success

Before starting, establish a baseline covering both the intended target and the safety unknowns. Because the only pooled benefit is central adiposity rather than weight, waist circumference at the navel is the primary tracked variable, averaged over three readings. Body weight and composition, a fasting metabolic panel, a lipid panel, and liver and kidney markers complete it, since human clearance routes are uncharacterised and trials excluded organ impairment.

Ongoing, re-measure waist circumference and body weight every 2 weeks, and repeat the full biochemical panel at 12 weeks and at the end of a 16-week cycle. Anyone on glucose-lowering medication should self-monitor fasting glucose daily for 2 weeks. If waist circumference has not moved by 12 weeks at full dose, the result matches the null trials and the cycle is reasonably ended.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|-----------|--------------------------|-----------------|---------------|
| Waist circumference | < 94 cm (men), < 80 cm (women) | The only outcome with pooled trial support | Measure at the navel, fasted, on waking; average three readings. Conventional risk cut-offs are higher (102 cm / 88 cm) |
| Waist-to-hip ratio | < 0.90 (men), < 0.85 (women) | Second pooled-significant outcome; tracks fat distribution | Same session as waist. Less sensitive to short-term fluid shifts than waist alone |
| Body weight and body fat percentage | 10–20% fat (men), 18–28% (women) | Detects whether any loss is fat or lean mass | Body composition scan preferred over scale alone; appetite suppression risks lean-mass loss |
| Fasting glucose | 75–86 mg/dL | Baseline safety check and additive-hypoglycaemia guard | 12-hour fast. Conventional range extends to 99 mg/dL; functional targets are tighter |
| HbA1c | 4.8–5.3% | Confirms no adverse glycaemic drift over a cycle | HbA1c is glycated haemoglobin, average blood sugar over about three months. No fasting required. Conventional cut-off for concern is 5.7% |
| Fasting insulin | 2–5 µIU/mL | Detects insulin-resistance change alongside waist reduction | Pair with fasting glucose in the same draw to calculate an insulin-resistance score |
| Leptin (the fat-tissue hormone signalling energy stores) | 4–6 ng/mL (men), 8–12 ng/mL (women) | The one biomarker that differed between groups in the longest trial | Fasted morning draw; highly sensitive to recent food intake and sleep loss |
| Lipid panel (triglycerides, HDL, LDL) | Triglycerides < 100 mg/dL; triglyceride-to-HDL ratio < 2.0 | Human trials showed no lipid benefit; measured as a safety check | HDL and LDL are the two main cholesterol-carrying particles in blood. 12-hour fast. The ratio is more informative than any single value |
| ALT and AST | ALT 10–26 U/L; AST 10–26 U/L | Human clearance route is uncharacterised; liver disease was a trial exclusion | ALT and AST are alanine and aspartate aminotransferase, two liver enzymes. Conventional upper limits run to about 40 U/L, well above the functional target |
| Creatinine and estimated glomerular filtration rate (a kidney-filtering measure) | eGFR > 90 mL/min/1.73 m² | Kidney disease was a trial exclusion criterion | Avoid heavy training and creatine loading for 48 hours before the draw |
| Blood pressure | < 120/80 mmHg | One trial reported within-group systolic changes; confirms no adverse shift | Seated, rested 5 minutes, averaged over three readings on separate days |
| Salivary cortisol (morning) | No established target for this use; track change from the individual's own baseline | Only relevant if using the extract for the stress endpoint | Collect within 30 minutes of waking on a non-workday; single readings are highly variable |

Qualitative markers matter at least as much here, because the primary claimed effect is subjective:

- Hunger between meals — rated 1 to 10 at a fixed time daily
- Time to satiety within a meal, and portion size left uneaten
- Frequency and intensity of food cravings, particularly evening cravings
- Digestive comfort — stool frequency and consistency, bloating, nausea
- Perceived stress and anxiety, if that is the reason for use
- Sleep quality and time to fall asleep, given evening dosing and absent trial data
- Training capacity and recovery, as a proxy for adequate fuelling

  
## Emerging Research

- **Stress, sleep, and neurotransmitter trial:** [NCT05232266](https://clinicaltrials.gov/study/NCT05232266), a Phase 2/3 randomised, double-blind, placebo-controlled trial of 500 mg twice daily in 129 adults, with perceived stress and salivary cortisol as primary endpoints plus sleep questionnaires and neurotransmitter panels. Completed May 2023; results remain unpublished.

- **No other registered trials:** A ClinicalTrials.gov search for this intervention returns exactly one study, the completed trial above. No trial is currently recruiting, so the near-term human evidence pipeline is effectively empty.

- **Mechanism arbitration:** The contradiction between the serotonin 2C receptor account of [Griggs et al., 2018](https://pubmed.ncbi.nlm.nih.gov/30353709/) and the raised neuropeptide Y and orexin observed by [Vitalone et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28713048/) is unresolved and determines whether central or peripheral targets are worth pursuing.

- **Vascular endpoints:** [Thunuguntla et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39770917/) reported improved blood-vessel function in high-fat-fed obese mice. Translating this to a human endothelial endpoint would open a longevity-relevant claim the current trial set does not address, and would strengthen the case.

- **Independent replication of the null findings:** The [independent trial of Arora et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25657901/) found nothing beyond placebo. A second adequately powered, non-industry-funded replication would most efficiently weaken or confirm the case, and none is registered.

- **Pooled-analysis re-examination:** [Jayawardena et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34758791/) concluded against recommending the extract on seven trials. Adding two or three larger independent trials would likely flip or firm that conclusion; with the current pipeline empty, it stands unchallenged.

- **Human pharmacokinetics:** No absorption, distribution, or clearance study of the pregnane glycosides exists in people. Until one is done, dosing, timing, and drug-interaction assessment all rest on assumption rather than measurement.

  
## Conclusion

*Caralluma fimbriata* is a wild Indian succulent eaten as food for generations and sold since the early 2000s as a concentrated capsule extract for curbing hunger. Pooling every controlled trial, one finding survives: a small reduction in waist measurement and waist-to-hip ratio. Body weight, body mass index, blood sugar, and blood fats do not move. The appetite claim that built the product's reputation is genuinely split — the earliest trial and the longest trial found reduced hunger and food intake, an independent trial found nothing, and pooling the whole set finds nothing.

How well the extract is tolerated is its strongest suit. Digestive upset and occasional skin rash are the reported effects, both mild and short-lived, and animal safety testing has been unusually thorough for a plant supplement. The real gaps are duration and independence: no trial has run beyond sixteen weeks, no human absorption study exists, and pregnancy remains untested with conflicting signals.

The evidence base carries a plain commercial fingerprint. Most positive trials used one company's branded extract, and several were funded or run by parties selling it; the clearly independent trial was the one that found nothing. No professional body has taken a position either way, so the conflicts here are commercial rather than institutional.

For someone already optimising nutrition and training, the honest reading is a small, well-tolerated, cheaply obtained waist effect resting on a thin and commercially interested evidence base.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**